Long-acting antipsychotic options for schizophrenia
Part of Mental health clinical trials.
This study looks at long-acting (extended-release) antipsychotic medicine options in people with schizophrenia, compared with regular tablets. You may be able to join if you were already part of a related earlier study or its real-world follow-up.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be able to sign consent forms yourself, or have a legally authorized representative sign for you
- Be allowed to take part under local laws (for example, not prevented by local legal rules)
- Have been randomly assigned to aripiprazole or paliperidone—either tablets or long-acting injections—in the earlier EULAST-I study, OR
- Have participated in the EULAST-I real-world (naturalistic) follow-up study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new version of an extended-release injection is as effective as the original in people with schizophrenia. The study helps ensure patients have access to a reliable treatment option.
This is an observational (non-intervention) study that follows adults with schizophrenia who are taking specific “atypical” antipsychotic medicines long-term. Researchers want to learn about patients’ experiences and outcomes while on these treatments.
This study tests whether a new long-acting injection of aripiprazole (a medication for schizophrenia) works the same as the current version. It helps understand how the drug is absorbed and may offer a more convenient treatment option for people with stable schizophrenia.
This study tests an extended-release form of the medication brexpiprazole, given as an injection, for people with schizophrenia. It aims to see how the drug moves through the body and how safe it is.
This trial tests a long-acting injectable form of cariprazine (AX251 LAI) for people with stable schizophrenia. You would receive one injection and stay at the clinic for 7 days to see how your body handles it and how well you tolerate it.
This trial tests a new medication called SEP-363856 over a long period for people with schizophrenia who are currently stable. It looks at how well the drug works and its safety over time.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.